BIOGEN INC. Accounts Payable
BIOGEN INC. (BIIB) had Accounts Payable of $358.50 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-04-29
- 2026-03-31: Accounts Payable, Current $358.50M.
- 2025-12-31: Accounts Payable, Current $432.00M.
- 2025-09-30: Accounts Payable, Current $413.10M.
- 2025-06-30: Accounts Payable, Current $408.40M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-03-31 | $358.50M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $432.00M 10-Q · filed 2026-04-29 | |
| 2025-09-30 | $413.10M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $408.40M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $391.50M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $424.20M 10-K · filed 2026-02-06 | |
| 2024-09-30 | $422.70M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $354.50M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $387.00M 10-Q · filed 2024-04-24 | |
| 2023-12-31 | $403.30M 10-K · filed 2025-02-12 | |
| 2023-09-30 | $440.10M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $445.40M 10-Q · filed 2023-07-25 | |
| 2023-03-31 | $491.20M 10-Q · filed 2023-04-25 | |
| 2022-12-31 | $491.50M 10-K · filed 2024-02-14 | |
| 2022-09-30 | $383.20M 10-Q · filed 2022-10-25 | |
| 2022-06-30 | $434.80M 10-Q · filed 2022-07-20 | |
| 2022-03-31 | $398.70M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $589.20M 10-K · filed 2023-02-15 | |
| 2021-09-30 | $427.90M 10-Q · filed 2021-10-20 | |
| 2021-06-30 | $375.30M 10-Q · filed 2021-07-22 | |
| 2021-03-31 | $430.40M 10-Q · filed 2021-04-22 | |
| 2020-12-31 | $454.90M 10-K · filed 2022-02-03 | |
| 2020-09-30 | $398.40M 10-Q · filed 2020-10-21 | |
| 2020-06-30 | $383.90M 10-Q · filed 2020-07-22 | |
| 2020-03-31 | $389.00M 10-Q · filed 2020-04-23 | |
| 2019-12-31 | $530.80M 10-K · filed 2021-02-03 | |
| 2019-09-30 | $382.20M 10-Q · filed 2019-10-22 | |
| 2019-06-30 | $377.10M 10-Q · filed 2019-07-24 | |
| 2019-03-31 | $378.00M 10-Q · filed 2019-04-24 | |
| 2018-12-31 | $370.50M 10-K · filed 2020-02-06 | |
| 2018-09-30 | $342.30M 10-Q · filed 2018-10-23 | |
| 2018-06-30 | $295.70M 10-Q · filed 2018-07-24 | |
| 2018-03-31 | $345.80M 10-Q · filed 2018-04-24 | |
| 2017-12-31 | $395.50M 10-K · filed 2019-02-06 | |
| 2017-09-30 | $298.70M 10-Q · filed 2017-10-24 | |
| 2017-06-30 | $330.30M 10-Q · filed 2017-07-25 | |
| 2017-03-31 | $316.40M 10-Q · filed 2017-04-25 | |
| 2016-12-31 | $279.80M 10-K · filed 2018-02-01 | |
| 2016-09-30 | $274.00M 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $225.90M 10-Q · filed 2016-07-21 | |
| 2016-03-31 | $271.30M 10-Q · filed 2016-04-21 | |
| 2015-12-31 | $267.40M 10-K · filed 2017-02-02 | |
| 2015-09-30 | $251.23M 10-Q · filed 2015-10-21 | |
| 2015-06-30 | $282.70M 10-Q · filed 2015-07-24 | |
| 2015-03-31 | $236.13M 10-Q · filed 2015-04-24 | |
| 2014-12-31 | $229.20M 10-K · filed 2016-02-03 | $229.18M 10-K · filed 2015-02-04 |
| 2014-09-30 | $233.63M 10-Q · filed 2014-10-22 | |
| 2014-06-30 | $224.93M 10-Q · filed 2014-07-23 | |
| 2014-03-31 | $212.81M 10-Q · filed 2014-04-23 | |
| 2013-12-31 | $219.91M 10-K · filed 2015-02-04 | |
| 2013-09-30 | $166.71M 10-Q · filed 2013-10-28 | |
| 2013-06-30 | $163.09M 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $165.21M 10-Q · filed 2013-04-25 | |
| 2012-12-31 | $204.00M 10-K · filed 2014-02-06 | |
| 2012-09-30 | $157.42M 10-Q · filed 2012-10-25 | |
| 2012-06-30 | $159.15M 10-Q · filed 2012-07-24 | |
| 2012-03-31 | $173.33M 10-Q · filed 2012-05-01 | |
| 2011-12-31 | $186.45M 10-K · filed 2013-02-05 | |
| 2011-09-30 | $159.20M 10-Q · filed 2011-10-28 | |
| 2011-06-30 | $170.75M 10-Q · filed 2011-07-26 | |
| 2011-03-31 | $159.14M 10-Q · filed 2011-04-21 | |
| 2010-12-31 | $162.53M 10-K · filed 2012-02-03 | |
| 2010-09-30 | $143.70M 10-Q · filed 2010-10-26 | |
| 2010-06-30 | $144.48M 10-Q · filed 2010-07-20 | |
| 2010-03-31 | $121.36M 10-Q · filed 2010-04-20 | |
| 2009-12-31 | $118.53M 10-K · filed 2011-02-04 | |
| 2009-09-30 | $108.55M 10-Q · filed 2009-10-21 | |
| 2008-12-31 | $107.42M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |